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Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a very rare aggressive hematopoietic malignancy. The median survival is 
approximately 12 months, and for patients >65 years the survival rate is 7 months, when only chemotherapy is administered. Clinically, 
it is characterized by skin involvement and most often bone marrow lesions accompanied by lymphadenopathy and in some cases 
hepato- and/or splenomegaly. The diagnosis is based on histopathological examination of the skin or bone marrow lesions and tumor 
cell immunophenotyping. The etiopathogenesis of the disease is not fully understood. Therapeutic decisions are based only on the 
results of a few retrospective analyses and case reports. This article presents the important role of allogeneic hematopoietic cell 
transplantation in the treatment of BPDCN.
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Introduction
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a very rare 
hematopoietic malignancy, characterized by an aggressive course and 
poor prognosis [1]. The disease was described in 1994, and in 2008 it 
was included in the World Health Organization (WHO) classification for 
the first time, in a group of acute myeloid leukemia (AML) and related 
neoplasms [2, 3]. In the latest WHO classification, a separate nosological 
unit in myeloid neoplasms and acute leukemia subgroup was defined, 
and therefore BPDCN is no longer classified as AML [4]. BPDCN is very 
rare, accounting for about 0.44% of all hematological cancers and 0.7% 
of acute leukemias, with an incidence of 2 per 10,000,000 people [5]. 
The disease mainly affects older people in the sixth–seventh decades 
of life with a higher incidence in males (M:F = 3:1), although cases in 
children and infants have also been reported [1, 6, 7]. The clinical picture 
of BPDCN is quite characteristic. Most patients have skin lesions in the 
form of single or multiple nodules or bruise-like plaques, brownish or 
red, between a few millimeters and a few centimeters in size. They are 
located in different parts of the body, often affecting the face, upper 
limbs, and torso, involving the dermis and subcutaneous tissue, without 
epidermal involvement, necrotic lesions, and vascular or inflammatory 
infiltrations. Due to the variable skin presentation, BPDCN is divided 
into three groups, namely, nodular (the most common), bruise-like, and 
disseminated with the presence of both nodular and bruise-like lesions. 
Mucosal presentation is rare [8, 9]. Skin biopsy is often the first test to 
diagnose the disease [10]. There are a few reports of local, limited skin 
involvement, including a series of cases as described by Ishibashi et al. 
[11]. In addition to the skin manifestations, bone marrow or, more rarely, 
extramedullary organs involvement are often observed, including the 
central nervous system, lungs, testicles, mediastinum, conjunctiva, 
stomach, nasopharynx, paranasal sinuses, and gums [12–16]. 
In the case of bone marrow infiltration, medium-sized blasts with 
irregular nucleus, large amounts of cytoplasm, devoid of azurophilic 
granules, and lack or blurred nucleoli are usually present (Fig. 1) [17]. 
Another rare variant is the infiltration of medium to large blasts with 
eccentric nuclei, regular round or oval in shape, with a fine, diffuse 
chromatin and one or more pronounced nucleoli, abundant, basophilic 
cytoplasm, fine vacuoles, and pseudopodia cytoplasmic protrusions, 
and clear Golgi zone located distantly from the nucleus (plasmablastic 
features) [18]. Immunophenotyping plays an extremely important role 
in the diagnostic process. The most important clusters of differentiation 
(CDs) expressed by the cells are CD4+, CD56+, CD123+, and TCL1+. 
The presence of CD38 antigen may be of therapeutic significance due 
to the potential to administer anti-CD38 antibodies. Cytogenetic and 
molecular studies play an auxiliary role. The most common lesions 
in the karyotype include 5q, 12p, 13q, 6q, 15p, and 9q deletions. In 
addition, reduced expression of tumor suppressors, RB1 and LATS2, 
as well as CDKN1B, CDKN2A, TP53, TET2, and PTE mutations are 
observed [19, 20]. Different predilection of cancer cells that are home 
to specific locations seems to be related to their maturity. The least 
mature group of CD34-expressing cells almost exclusively infiltrates 
the bone marrow, does not infiltrate the skin and extramedullary organs, 
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and has the tendency to disseminate via peripheral blood. Due to 
accompanying cytopenias, the course of the disease is similar to that 
of leukemia [21]. On the contrary, immunophenotypically mature cells 
infiltrate the extramedullary organs and the disease may resemble 
aggressive lymphomas. Because of this, in the past the disease 
was classified in the group of both lymphomas and acute leukemia 
under various previously functioning names, including CD4+CD56+ 
cutaneous neoplasm/lymphoma, blastic NK-cell lymphoma/leukemia, 
agranular CD4+CD56+ hematodermic neoplasm, hematodermic 
neoplasm CD4+/CD56+, and blastic plasmocytoid dendritic cell 
neoplasm. Most BPDCN studies published to date are retrospective. 
The first prospective study was focused on the use of SL401 protein 
as targeted treatment [22]. By 2019, 356 BPDCN cases have been 
reported [23]. Only 14 patients have been described in the Polish 
literature so far [24–27]. Therefore in this article we present four 
new cases of BPDCN and discuss the optimal treatment in Poland, 
with particular emphasis on the role of allogeneic hematopoietic cell 
transplantation (allo-HCT).
Case study
All patients were men >40 years of age (Tab. I). Except in one 
case, skin presentation was predominant in the clinical picture. The 
extramedullary involvement included lymph nodes, spleen, and 
liver. In complete blood count (CBC), normal or moderately elevated 
white blood cell counts associated with cytopenias in other lines, i.e., 
thrombocytopenia in all, and anemia in three out of four patients have 
been observed. In peripheral blood smear, the presence of abnormal 
cells (blasts or lymphoid cells) has been described. All patients 
had significant bone marrow infiltration, ranging from 70% to 92%. 
Interestingly, all four typical antigens (CD4, CD56, CD123, TCL1) were 
expressed only in a single patient. In one case, CD4 antigen was absent, 
and CD56 expression was dim. However, in two patients plasmacytoid 
dendritic cell antigens were detected (CD123 and TCL1 or CD123 
only); in the other two, these antigens were not determined, and the 
diagnosis was based on typical cell morphology. The expression of 
HLA-DR, TdT, and CD38 was observed in three out of four patients. 
In two patients, in whom cytogenetic and molecular tests were 
performed, the karyotype was normal and mutations in FMS-like 
receptor tyrosine kinase-3 (FLT3),nucleophosmin 1 (NPM1), and 
CCAAT/enhancer binding protein alpha (CEBPA) genes were not 
detected. Three patients were qualified for induction treatment 
with the hyperCVAD/MA regimen (cyclophosphamide, vincristine, 
doxorubicin, dexamethasone, methotrexate, and cytosine 
arabinoside). All achieved complete remission (CR) in cytological and 
cytometric examination, and two of them continued the treatment with 
either two or one cycle (Cases 1 and 3, respectively), followed by 
allo-HCT after myeloablative conditioning (MAC) from an unrelated, 
fully compatible donor with total body irradiation (TBI) at a dose of 
12 Gy + cyclophosphamide + antithytocytic globulin (Case 1) or from 
an unrelated donor with a single mismatch at the B locus (TBI 12 Gy + 
cyclophosphamide + anti-thymocyte globulin) (Case 3). In Case 4, the 
treatment was de-escalated due to infectious complications and was 
continued with five cycles of CHOP (cyclophosphamide, daunorubicin, 
and vincristine prednisone). The patient had a relapse while waiting 
for the transplantation procedure. The last patient (Case 2) was not 
eligible for intensive treatment and received three cycles of CHOP. 
Despite the initial partial response (PR), disease progression was 
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Fig. 1. Microscopic image of BPDCN cells in the bone marrow (own collection) 
The images show atypical, polymorphic BPDCN cells. Some of them have a blast-like morphology (A, D), while 














    
Fig. 1. Microscopic image of BPDCN cells in the bone marrow (own collection)
The images show atypical, polymorphic BPDCN cells. Some of them have a blast-like morphology (A, D), while others resemble aggressive malignant lymphoma cells (B, C)
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observed, including recurrence of skin lesions and development of 
neurological symptoms. The patient died shortly after the progression 
onset.
Discussion
The presented cases can serve as a good illustration of a typical 
course of the disease. The dominant clinical symptom was skin 
lesions (mainly “nodular” and “bruise like”). One patient had a very 
rare form of leukemia without skin involvement – by 2018, only 
39 such cases were reported [16]. Skin lesions may imitate other 
diseases. In one of these patients, diagnostic process was delayed 
for 6 months from the onset of the first skin lesions, which highlights 
the need to rapidly perform biopsies of atypical, persistent skin 
lesions. According to the literature, BPDCN skin lesions have 
been erroneously described as leprosy, melanoma, diffuse large 
B-cell lymphoma (DLBCL), and systemic lupus erythematosus 
[18, 28, 29]. Differential diagnostics of the skin lesions should include 
dermatological diseases, such as psoriasis, eczema, and lichen 
planus [30]. A patient with local infiltration of the paranasal sinuses 
(without skin and bone marrow involvement) has also been described 
[16, 31]. Cases of BPDCN development have also been observed 
in patients with previously diagnosed myelodysplastic syndrome 
[1, 15, 32]. Table II shows differential diagnosis of BPDCN. Computed 
tomography (CT) provides some help due to the typical image of the 
skin and subcutaneous tissue – these changes are round or oval 
(“ovate”) with uniform density of soft tissues [33]. In the faciocranial 
CT scan performed in one of the patients with skin lesions located 
on the left half of the face, an oval, well-delimited hyperdensive 
structure in subcutaneous fat measuring 24 x 12 mm was observed 
on the same side of the face. Positron emission tomography (PET) 
combined with CT may be needed to identify patients with disease 
limited to a single location. The SUVmax value is not high, but is 
usually in the range of 2.4–3.5 [11, 34].
Diagnostics
The most useful diagnostic tool is bone marrow immunophenotyping 
using flow cytometry. The diversity of expression of antigens, including 
those typical for BPDCN, is significant and often not all antigens listed 
Table I. Clinical characteristics of the described cases 
 Case 1 Case 2 Case 3 Case 4
Age 67 74 46 55
Sex M M M M
Skin lesions Brown, flat, or slightly raised, 
“bruise-like”, on the torso 
0.5–1.5 cm; under the shoulder 
blade 8 x 5 cm
Brown, flat, or slightly 
raised, (“bruise like”) 
on the torso and in the 
lumbosacral region




+ + + +
Splenomegaly in diagnostic 
imagining
+ + + +
Hepatomegaly in diagnostic 
imagining
+ + – +
WBC (G/L) at diagnosis 11 24 5.8 5.29
Hb (g/dL) 10.6 13 7.3 7.5
PLT (G/L) 43 70 70 87
Peripheral blood film 27% blasts 15% blasts 22% blasts 14.5% lymphoid cells
Blast infiltrates in the bone 
marrow (%)
70 85 81 92
Immunophenotype (major 
antigens)
CD4+, CD56+, CD123+, TdT+, 
CD 45+, HLA-DR+, CD71+, 
NG2+, CD33+, CD38+, TCL1+
CD123+, CD 56±, 
CD45RA+, CD7+, 
CD33+, CD45+, CD38+, 
CD4-, HLA DR+, CD36+, 
CD99+
CD4+, CD56+, TdT+, CD43+, 
CD68+, CD99+, CD33+
CD56+, CD4+, TdT +, CD7±, 
CD43+, CD33+, CD38+, HLA-
DR+, CD36+
Cytogenetics Not performed Normal karyotype Normal karyotype Not performed
Molecular assays Not performed FLT3 ITD(-), NPM1 (-) FLT3 ITD(-), NPM1(-), CEBPA(-) Not performed
Treatment 3 x hyperCVAD/MA + allo-HCT- 
MUD
3 x CHOP 2 x hyperCVAD/MA + allo-
HCT- MMUD
1 x hyperCVAD/MA + 5 x 
CHOP
Response to the treatment CR PR CR NR
Survival (months) 36+ 3 25+ 9+
M – male; WBC – white blood cells; Hb – hemoglobin; PLT – platelets; hyperCVAD/MA – cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytosine arabinoside; 
CHOP – cyclophosphamide, doxorubicin, vincristine, prednisone; allo-HCT-MUD – allogeneic hematopoietic stem cell transplantation-match unrelated donor; allo-HCT-MMUD – 
allogeneic hematopoietic stem cell transplantation-mismatch unrelated donor; FLT3-ITD – FMS-like receptor tyrosine kinase-3 internal tandem duplication; NPM1 – nucleophosmin 1; 
CEBPA – CCAAT/enhancer binding protein α; CR – complete remission; PR – partial remission; NR –  no response
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as characteristic of this disease are detected. All major antigens were 
present in only one patient from our cohort. The second did not show 
CD4, and CD56 expression was low. In the next two patients, the 
cytometric analysis was carried out to an incomplete extent, and 
CD123 and TCL1 expression was not assessed. However, a few 
cases lacking CD4 and/or CD56 expression were described in the 
literature [10, 35, 36, 37]. In addition to the above two, at least one 
antigen typical for plasmacytoid dendritic cells should be present: 
CD123, BDCA2/CD303, TCL1, CLA, CD2AP in the absence of 
markers specific for B cells (CD19, CD79a), T cells (CD3), as well 
as myeloid (myeloperoxidase) and monocytic cells (CD11c, CD163, 
lysozyme). Other commonly observed antigens include CD68 (in 
50% of cases), CD43 (95% of cases), TdT (20%–60% of cases), 
CD45, CD45RA, as well as CD5, CD7, CD33, and sporadically also 
CD117 [38]. These antigens were found in the studied patients in 
various configurations; however, CD4 or CD56 were always present. 
In unclear cases, histopathological examination should be the 
standard practice. All of these patients underwent trepanobiopsy 
and in two cases lymph nodes were collected for histopathological 
examination. Skin biopsy was performed in one case. Interestingly, 
CD38 expression was commonly observed in the studied group. This 
antigen was positive in three out of four patients. To date, there are 
no data on the expression of this marker in BPDCN, even though 
CD38 expression suggests the possibility of daratumumab treatment 
– the first experience with this therapy is promising [39]. One of the 
CD38-positive patients, who relapsed during the preparation for allo-
HCT, was considered for daratumumab therapy; however, the patient 
progressed while waiting for approval to use daratumumab. CD123 
expression, typical for plasmacytoid dendritic cells, was confirmed 
only in two patients with BPDCN. CD34, maturation antigen, was 
negative in all the studied patients. Some researchers suggest that 
CD34 expression excludes the diagnosis of BPDCN, while others do 
Table II. Differential diagnosis involving diseases that may resemble BPDCN
Disease Age at onset (median) Skin
Organ 
involvement
The most common 














No standards (in the US, 
treatment with SL401 
protein)
No data; OS 
12 months
PCLBCL 70 years, mainly 
females
Red or purple-red 









R-CHOP + Rtx From 36% 45% to 
100%, depending 
on the number of 
skin lesions
AML (M5) 67 years slightly 
more often in 
females







TdT±, CD33+, CD34+ 
MPO±, CD117+, 
CD13+, CD15+
DAC In patients 





or tumors on the 
skin of the trunk 
and extremities or 
a single tumor in 
the nasopharynx 








CD5±, CD7±, CD4+, 
CD8+
Rtx 50 Gy and prevention of 
changes in CNS; possibly rtx 
and chtx
42%
C-ALCL 60 years, mostly 
males
Tumors, nodules, 
reddish, single or 
multiple, often with 
ulceration
Lymph nodes – 
secondary
CD30+, CD4+, 
CLA+; no EMA and 
ALK
Surgical or Rtx 90%













Systemic chtx as in AML As in AML












30–60 years, M = F Pink to bluish red 
papules 1–3 mm, 
Wickham mesh








As in general 
population




with adherent scales 
in typical areas 
(knee and elbow 
joints, scalp)
Does not occupy 
internal organs




As in the general 
population
BPDCN – blastic plasmacytoid dendritic cell neoplasm; PCLBCL – primary cutaneous large B-cell lymphoma; AML – acute myeloid leukemia; ENKTCL – extranodal NK/T-cell lymphoma, 
nasal type; C-ALCL – primary cutaneous anaplastic large cell lymphoma; MS – myeloid sarcoma; PTCL NOS –  peripheral T-cell lymphoma, not otherwise specified; Rtx – radiotherapy; 
Chtx –  chemotherapy.
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not agree with this criterion [40, 41]. Considering the high antigenic 
diversity, Salva et al. [42] highlighted the need to search for other 
markers characteristic of BPDCN, suggesting frequent expression of 
CD31/PECAM (positive in 8/10 of cases studied). The aforementioned 
antigen was not assessed in our cohort.
Cytogenetic and molecular tests play an important role in the 
diagnosis. In two examined patients, no changes in chromosome 
structure were found, although BPDCN is often associated with 
a complex karyotype (74%) and suppressor gene abnormalities [10]. 
The literature describes the case of a patient with BPDCN diagnosed 
in nodular skin lesion biopsy, who despite the lack of morphological, 
immunohistochemical, and immunophenotypic changes in the bone 
marrow, had abnormalities in chromosomes 12 and 22 [10]. TET2 
is one of the most commonly mutated genes (54%) [43]. Krause et 
al. [44] described a patient with protoporphyria with TET2 mutation, 
who developed BPDCN after 3 years of primary diagnosis. Table III 
summarizes the frequency of other common molecular abnormalities, 
including mutations, epigenetic and molecular changes, and signaling 
pathways, and their potential significance in targeted therapy.
Treatment
There is no standard protocol for BPDCN treatment. Treatment 
decisions are often complicated by the advanced age of the patients 
(median incidence of 60–70 years) and comorbidities. Therefore, 
in each of the described cases, treatment decisions were made 
individually. Three patients were treated with intensive hyperCVAD/
MA (in two patients, Cases 3 and 4, with intrathecal prophylaxis of 
central nervous system involvement) and subsequent allo-HCT. 
Prophylaxis of CNS involvement seems to be an important element of 
the treatment due to frequent latent CNS involvement, as confirmed 
by Martin-Martin in 6/10 of patients studied [12]. All three patients 
treated with hyperCVAD/MA achieved CR after the first cycle. Due 
to high frequency of life-threatening infections, in a single patient the 
treatment was de-escalated and continued with CHOP; however, 
it led to rapid relapse. The remaining patients were treated with 
hyperCVAD/MA, followed by allo-HCT with MAC.
The choice of the treatment in the studied patients was based on 
the experience of other treatment centers. The results of French 
retrospective studies show that a combination of drugs active against 
lymphoid (methotrexate, L-asparaginase, and dexamethasone) and 
myeloid lineage (anthracycline) is the most beneficial [45]. Several 
large retrospective studies compared responses after induction 
protocol used in the treatment of acute lymphoblastic leukemia (ALL) 
– hyperCVAD vs. GIMEMA ALL and acute myeloid leukemia protocol. 
The efficacy of ALL protocol (hyperCVAD/MA) was higher with CR 
of about 90% [1, 46]. According to Pagano, overall survival (OS) in 
patients treated with the AML protocol was 7.1 months vs. 12.3 months 
in patients treated with the ALL protocol [1]. Longer survival (19 vs. 
11 months) was shown in another study comparing ALL protocols: 
hyperCVAD vs. VPDL (vincristine, methylprednisolone, daunorubicin, 
and L-asparaginase) [47]. Based on these data, hyperCVAD/MA 
Table III. Targeted therapies for BPDCN treatment
Mechanism of action Drug Notes References
BCL-2 inhibition Venetoclax Sensitivity of BPDCN cells to a drug at least as 
observed in AML;
Ongoing recruitment – NCT03485547
Montero et al. [58] and 
Grushchack et al. [56]
BET inhibition BET inhibitors (OTX015) NR3C1 deletion (5q31) and lincRNA-3q fusion – 
resistant to GS (glucocorticoid receptor mutation) 
– poor prognosis
Emadali et al. [59]
Overexpression of the LXR gene – 
inhibition of the NF-kB pathway
LXR agonist Cholesterol homeostasis abnormalities in BPDCN; 
agonists probably cross the blood–brain barrier
Ceroi et al. [60]
Inhibition of BRD4 and 
downregulation of TCF4
TCF4 is the main pleiotropic regulator of BPDCN 
cell survival (treatment may be more effective than 
classical targeted therapies) 
Kleppe et al. [61] and Ceribelli 
et al. [62]
Binding to IL-3 receptor SL-401 Single prospective study in BPDCN;
intrathecal administration of SL401 is also considered
Frankel et al. [22]
Inhibition of the NFkB pathway Bortezomib The sensitivity of BPDCN cells to bortezomib was 
confirmed
Sapienza et al. [19]
Restoration of p27 suppressor 
function (CDKN1B)
Rapamycin Wiesner et al. [63]
DNA hypomethylation Decitabine
Azacitidine
More effective than bortezomib Sapienza et al. [64]
CAR T cells (anti-CD123) UCART 123 NCT03190278 – Phase I study in the United States








PD1/PDL1 inhibition Pembrolizumab, nivolumab Potential role – requires further research Aung et al. [65]
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treatment was initiated in all of our patients who were eligible for 
therapy. However, none of the above studies confirmed long-term 
remissions (OS, 29 months) and the authors emphasize the need to 
intensify the treatment [48].
Allo-HSCT
Allogeneic hematopoietic cell transplantation appears to be main 
curative treatment, which, in a retrospective study of a group of 
34 patients from the European Group for Blood and Bone Marrow 
Transplantation (EBMT) register, allowed to achieve long-term OS 
in 41% and disease-free survival (DFS) in 33% of patients [49]. 
Better results were reported by American centers: in the group of 
37 patients, 3-year progression-free survival (PFS) was 69%, and 
3-year OS 61% and 62%, for MAC and reduced intensity conditioning 
(RIC) conditioning, respectively [50]. Conditioning is not specific to 
BPDCN, the choice of the protocol is based on age and comorbidities 
of the patient. The studies published so far suggest using MAC 
conditioning before allo-HCT whenever possible. Although the 
results of retrospective analysis from eight centers from the United 
States and Canada showed a similar 3-year PFS (55%) in both 
MAC (n = 20) and RIC (n = 17) groups, and a fairly good 3-year 
OS of 61% and 55%, respectively, the EBMT study showed long-
term survival only after MAC conditioning. The procedure should 
be carried out in the first remission (CR1), as no long-term survival 
in subsequent remissions was observed. High-dose chemotherapy 
combined with autologous hematopoietic stem cell transplantation 
(auto-HCT) is a potential alternative to allo-HCT. However, the data 
on the effectiveness of auto-HCT are contradictory. In one Japanese 
study (n = 11), auto-HCT was superior to allo-HCT in CR1, namely: 
4-year OS was achieved in 82% patients treated with auto-HCT vs. 
69% patients treated with allo-HCT and 4-year PFS in 72% vs. 60%, 
respectively [51]. However, these results were contradicted by Reimer 
et al. [52], who showed that three out of four studied patients died due 
to relapse after auto-HCT. Similarly, in the analysis of US registers 
(n = 8), 1-year PFS and OS were 11%. The explanation for this may 
be different eligibility criteria – some patients were not in CR1 and the 
median age of the studied population was higher. In light of the above 
discrepancies, only allo-HCT remains a recommended therapeutic 
option (Leukemia and Lymphoma Society). Such treatment was used 
in two patients from our cohort. Hematopoietic cell transplantation in 
both patients was preceded by MAC based on cyclophosphamide 
and TBI. Antithymocyte globulin, cyclosporin, and methotrexate were 
used in immunosuppressive therapy. Hematopoietic stem cells were 
derived from peripheral blood (in the first patient – 7.13 x 10^6/kg 
bw CD34+ cells, and 5.52 x 10^6/kg bw in the second). Apart from 
infectious and cutaneous GvHD, in both cases no other serious 
complications were observed. These patients remain in CR from 
2016 and 2018 to date. In the other two patients, who did not undergo 
allo-HCT, treatment failure was observed.
Patients diagnosed with BPDCN subjected to retrospective analysis 
in Polish centers had a typical presentation: the median incidence 
was 67 years, male sex predominated (M:F 9:5), all patients had skin 
involvement, and lymph nodes were the most common extramedullary 
organs involved. In the vast majority the expression of CD4 and 
CD56 was observed, and in several cases CD123 was positive. 
Unfortunately, most of the patients were treated with non-intensive 
protocols, i.e., CHOP, CHOEP (cyclophosphamide, doxorubicin, 
vincristine, etoposide, prednisone), or CVP (cyclophosphamide, 
vincristine, prednisone). Some received more intensive treatment, 
i.e., IVAC (etoposide, ifosfamide, and cytarabine), AraC + Mtx 
(cytarabine and methotrexate). Only a single patient, who was 
treated according to the G-MALL T-LBL 2004 protocol, underwent 
allogeneic bone marrow transplantation and was the only one to 
achieve long-term survival of at least 80 months. In another patient 
treated according to the protocol for AML, allo-HCT was planned but 
not performed. Eight patients died and no data are available on the 
survival of the remaining patients. The results of patients from other 
Polish centers are consistent with our experience – allo-HCT gives 
a chance for cure in BPDCN [24–27].
New therapies
Due to poor outcomes of the standard treatment there is a need 
to develop new, more promising treatment strategies. The drugs 
and their mechanism of action shown to be effective in prospective 
studies are listed in  table III. Among them, only tagraxofusp-erzs 
(Elzonris) has been approved for BPDCN treatment in children 
and adults in the United States so far. In Europe, the approval is 
still pending. Tagraxofusp-erzs is a fusion protein (called SL401) 
consisting of interleukin IL3A conjugated with tetanus toxin. The drug 
targets IL3 receptor on cancer cells and in Phase I and II studies, 
response rate reached 78% with 55% of complete responses [22]. 
It can be used both in the first and second lines of treatment, and 
importantly, it can be used in several lines of treatment as the cancer 
cells retain sensitivity to SL401 protein at relapse [53]. Usually, after 
remission, allo-HCT is suggested. The limitations of the use of the 
drug are adverse effects, including the most significant – capillary 
leak syndrome, which affected 55% of the patients. In children, 
the outcome is worse, and the responses shorter [54]. The reason 
for this is not clear. One of the reasons is that the biology of the 
disease in children is slightly different. It is confirmed by the fact that, 
unlike in adults, longer survivals are observed in cases without skin 
involvement [55]. In salvage therapy, other drugs are tested. Strong 
expression of Bcl-2 in BPDCN compared to pDC cells encouraged the 
use of venetoclax and the expression of CD38 suggests a potential to 
use daratumumab. Grushchak et al. [56] described a patient with CR 
and survival of at least 10 months after 5-month venetoclax therapy, 
while Iversen et al. [39] showed remissions after using daratumumab 
in monotherapy. Another protocol that has recently proved effective 
in individual cases consisting of bortezomib, lenalidomide, and 
dexamethasone. This protocol, without success, was used in one of 
our patients in progression [57].
Conclusion
BPDCN is a challenge for doctors of various specialties. The difficulty 
in diagnosing the disease is associated with a varied clinical picture 
and rare occurrence. The disease is characterized by rapid relapses 
despite initial sensitivity to treatment, and long-term remissions 
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are observed after intensive treatment protocols combined with 
allogeneic bone marrow transplantation. Increasing numbers of 
studies on the etiopathogenesis of BPDCN and the use of targeted 
drugs should translate into increase in the cure rate or prolonged 
survival, especially in patients who are not candidates for intensive 
treatment and allo-HCT.
Authors’ contributions
MB – gave the study idea. EU, JMZ – contributed to the study 
concept. EU – was responsible for collecting data and writing the 
manuscript. JMZ – carried out editing, evaluation, and acceptance 
of the manuscript. KL – was responsible for image processing, 






The work described in this article has been carried out in accordance 
with The Code of Ethics of the World Medical Association (Declaration 
of Helsinki) for experiments involving humans; EU Directive 2010/63/
EU for animal experiments; uniform requirements for manuscripts 
submitted to biomedical journals.
[1] Pagano L, Valentini CG, Pulsoni A, et al. Blastic plasmacytoid dendritic 
cell neoplasm with leukemic presentation: an Italian multicenter 
study. Haematologica 2013;98:239–46.
[2] Adachi M, Maeda K, Takekawa M, et al. High expression of CD56 
(N‐CAM) in a patient with cutaneous CD4‐positive lymphoma. Am J 
Hematol 1994;47:278–82.
[3] Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World 
Health Organization (WHO) classification of myeloid neoplasms 
and acute leukemia: rationale and important changes. Blood 
2009;114:937–51.
[4] Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World 
Health Organization classification of myeloid neoplasms and acute 
leukemia. Blood 2016;127:2391–405.
[5] Bueno C, Almeida J, Lucio P, et al. Incidence and characteristics 
of CD4+/HLA DRhi dendritic cell malignancies. Haematologica 
2004;89:58–69.
[6] Jegalian AG, Buxbaum NP, Facchetti F, et al. Blastic plasmacytoid 
dendritic cell neoplasm in children: diagnostic features and clinical 
implications. Haematologica 2010;95:1873–9.
[7] Shimomura M, Asano T, Furue A, et al. Effective treatment of 
a childhood blastic plasmacytoid dendritic cell neoplasm with 
a cutaneous tumor alone by stem cell transplantation with reduced 
intensity conditioning. Indian J Hematol Blood Transfus 2016;32:26–31.
[8] Julia F, Petrella T, Beylot-Barry M, et al. Blastic plasmacytoid dendritic 
cell neoplasm: clinical features in 90 patients. Br J Dermatol 
2013;169:579–86.
[9] Viviano M, Cocca S, Miracco C, Parrini S. Blastic plasmacytoid 
dendritic cell neoplasm: a rare case of gingival lesion with leukaemic 
presentation. BMJ Case Rep 2018;2018:bcr2018224623.
[10] Tang Z, Tang G, Wang SA, et al. Simultaneous deletion of 3'ETV6 and 
5'EWSR1 genes in blastic plasmacytoid dendritic cell neoplasm: case 
report and literature review. Mol Cytogenet 2016;9:23.
[11] Ishibashi N, Maebayashi T, Aizawa, T et al. Radiation therapy for 
cutaneous blastic plasmacytoid dendritic cell neoplasm: A case 
report and review of the literature. Int J Clin Exp Med 2015;8:8204–9.
[12] Martín-Martín L, Almeida J, Pomares H, et al. Blastic plasmacytoid 
dendritic cell neoplasm frequently shows occult central nervous 
system involvement at diagnosis and benefits from intrathecal 
therapy. Oncotarget 2016;7:10174–81.
[13] Da Silva Barros Romão CM, dos Santos Júnior CJ, Leite LAC, et 
al. Blastic plasmacytoid dendritic cell neoplasm with pulmonary 
involvement and atypical skin lesion. Am J Case Rep 2017;18:692–5.
[14] Deng W, Yang M, Kuang F, et al. Blastic plasmacytoid dendritic 
cell neoplasm in children: a review of two cases. Mol Clin Oncol 
2017;7:709–15.
[15] Chamoun K, Loghavi S, Pemmaraju N, et al. Early detection of 
transformation to BPDCN in a patient with MDS. Exp Hematol Oncol 
2018;7:26.
[16] Lee SE, Park HY, Kwon D, Jeon YK, Kim WY. Blastic plasmacytoid 
dendritic cell neoplasm with unusual extracutaneous manifestation: 
two case reports and literature review. Medicine (Baltimore) 
2019;98:e14344.
[17] Dharmani PA, Mittal NM, Subramanian PG, et al. Blastic plasmacytoid 
dendritic cell neoplasm: report of two pediatric cases. Indian J Pathol 
Microbiol 2015;58:72–6.
[18] Sandes AF, de Castro IN, Miura TE, et al. Bone marrow infiltration by 
cells resembling plasmablasts in a patient with blastic plasmacytoid 
dendritic cell neoplasm. J Hematopathol 2011;4:123–6.
[19] Sapienza MR, Fuligni F, Agostinelli C, et al. Molecular profiling of 
blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern 
and suggests selective sensitivity to NF-kB pathway inhibition. 
Leukemia 2014;28:1606–16.
[20] Laribi K, Denizon N, Besançon A, et al. Blastic plasmacytoid dendritic 
cell neoplasm: from origin of the cell to targeted therapies. Biol Blood 
Marrow Transplant 2016;22:1357–67.
[21] Steinberg A, Kansal R, Wong M, et al. Good clinical response in 
a rare aggressive hematopoietic neoplasm: plasmacytoid dendritic 
cell leukemia with no cutaneous lesions responding to 4 donor 




A c t a  H a e m a t o l o g i c a  P o l o n i c a
[22] Frankel AE, Woo JH, Ahn C, et al. Activity of SL-401, a targeted therapy 
directed to interleukin-3 receptor, in blastic plasmacytoid dendritic 
cell neoplasm patients. Blood 2014;124:385–92.
[23] Safaei A, Monabati A, Mokhtari M, Solhjoo F, Montazer M. Blastic 
plasmacytoid dendritic cell neoplasm; a report of three cases. Iran J 
Med Sci 2019;44:74–8.
[24] Owczarczyk-Saczonek A, Sokołowska-Wojdyło M, Olszewska B, et al. 
Clinicopathologic retrospective analysis of blastic plasmacytoid 
dendritic cell neoplasms. Postepy Dermatol Alergol 2018;35:128–38.
[25] Targoński Ł, Kwapisz D, Rymkiewicz G, Walewski J. Blastic 
plasmacytoid dendritic cell neoplasm (BPDCN) — clinical features, 
diagnosis, and treatment in the experience from a single institution. 
Onkol Prakt Klin 2013;9:230–8.
[26] Szczepaniak A, Machnicki M, Gniot M, et al. Germline missense NF1 
mutation in an elderly patient with a blastic plasmacytoid dendritic 
cell neoplasm. Int J Hematol 2019;110:102–6.
[27] Żychowska M, Batycka-Baran A, Woźniak Z, Maj J. Blastic plasmacytoid 
dendritic cell neoplasm: a rare lymphoma of extremely aggressive 
course. Postepy Dermatol Alergol 2017;34:504–6.
[28] León-Martínez G, Meillón-García L, Morales-Polanco M, Soler-
Montecinos L, Ortiz-Hidalgo C. Unusual morphologic presentations 
of blastic plasmacytoid dendritic cell neoplasm: report of two 
cases misdiagnosed as melanoma and leprosy. Int J Surg Pathol 
2014;22:76–82.
[29] Chang HJ, Lee MD, Yi HG, et al. A case of blastic plasmacytoid dendritic 
cell neoplasm initially mimicking cutaneous lupus erythematosus. 
Cancer Res Treat 2010;42:239–43.
[30] Cui XB, Jin J, Pang XL, et al. A case of blastic plasmacytoid dendritic 
cell neoplasm with ecchymotic lesions on the whole body. Int J Clin 
Exp Pathol 2014;7:4391–9.
[31] Dunlap QA, Day KE, Borak SG, Woodworth BA. Pathology quiz case: 
plasmacytoid dendritic cell neoplasm. Allergy Rhinol (Providence) 
2014;5:50–2.
[32] Kong QT, Zhang M, Sang H, et al. Blastic plasmacytoid dendritic cell 
neoplasm of the skin associated with myelodysplastic syndrome. 
Dermatol Online J 2015;21:18.
[33] Jeong D, Choi JW, Jeong K, Sokol L. CT findings associated with blastic 
plasmacytoid dendritic cell neoplasm: a case report. Acta Radiol 
Open 2016;5:205846011665768.
[34] Sugimoto KJ, Shimada A, Yamaguchi N, et al. Sustained complete 
remission of a limited-stage blastic plasmacytoid dendritic cell 
neoplasm followed by a simultaneous combination of low-dose 
DeVIC therapy and radiation therapy: a case report and review of the 
literature. Int J Clin Exp Pathol 2013;6:2603–8.
[35] Ascani S, Massone C, Ferrara G, et al. CD4-negative variant of CD4+/
CD56+ hematodermic neoplasm: description of three cases. J Cutan 
Pathol 2008;35:911–5.
[36] Argyrakos T, Rontogianni D, Karmiris T, et al. Blastic natural killer (NK)-
cell lymphoma: report of an unusual CD4 negative case and review 
of the CD4 negative neoplasms with blastic features in the literature. 
Leuk Lymphoma 2004;45:2127–33.
[37] Takiuchi Y, Maruoka H, Aoki K, et al. Leukemic manifestation of 
blastic plasmacytoid dendritic cell neoplasm lacking skin lesion: 
a borderline case between acute monocytic leukemia. J Clin Exp 
Hematop 2012;52:107–11.
[38] Cota C, Vale E, Viana I, et al. Cutaneous manifestations of blastic 
plasmacytoid dendritic cell neoplasm-morphologic and phenotypic 
variability in a series of 33 patients. Am J Surg Pathol 2010;34:75–87.
[39] Iversen KF, Holdgaard PC, Preiss B, Nyvold CG, Plesner T. Daratumumab 
for treatment of blastic plasmacytoid dendritic cell neoplasm. 
A single-case report. Haematologica 2019;104:e432–3.
[40] Garnache-Ottou F, Feuillard J, Ferrand C, et al. Extended diagnostic 
criteria for plasmacytoid dendritic cell leukaemia. Br J Haematol 
2009;145:624–36.
[41] Martín-Martín L, López A, Vidriales B, et al. Classification and 
clinical behavior of blastic plasmacytoid dendritic cell neoplasms 
according to their maturation-associated immunophenotypic profile. 
Oncotarget 2015;6:19204–16.
[42] Salva KA, Haemel AK, Pincus LB, et al. Expression of CD31/PECAM-1 
(platelet endothelial cell adhesion molecule 1) by blastic plasmacytoid 
dendritic cell neoplasms. JAMA Dermatol 2014;150:73–6.
[43] Jardin F, Ruminy P, Parmentier F, et al. TET2 and TP53 mutations are 
frequently observed in blastic plasmacytoid dendritic cell neoplasm. 
Br J Haematol 2011;153:413–6.
[44] Krause JR, Baugh L, Swink A, Burch M. Blastic plasmacytoid dendritic 
cell neoplasm following acquired erythropoietic protoporphyria. 
Proc (Bayl Univ Med Cent) 2017;30:450–1.
[45] Poret E, Vidal C, Desbrosses Y, et al. How to treat blastic plasmacytoid 
dendritic cell neoplasm (BPDCN) patients: results on 86 patients of 
the French BPDCN Network. Blood 2015;126:456.
[46] Tsagarakis NJ, Kentrou NA, Papadimitriou KA, et al. Acute 
lymphoplasmacytoid dendritic cell (DC2) leukemia: results from the 
Hellenic Dendritic Cell Leukemia Study Group. Leuk Res 2010;34:438–46.
[47] Kim HS, Kim HJ, Kim SH, et al. Clinical features and treatment 
outcomes of blastic plasmacytoid dendritic cell neoplasm: a single-
center experience in Korea. Korean J Intern Med 2017;32:890–9.
[48] Pemmaraju N, Thomas DA, Kantarjian H, et al. Analysis of outcomes 
of patients (pts) with blastic plasmacytoid dendritic cell neoplasm 
(BPDCN). J Clin Oncol 2012;30:6578.
[49] Roos-Weil D, Dietrich S, Boumendil A, et al. Stem cell transplantation 
can provide durable disease control in blastic plasmacytoid dendritic 
cell neoplasm: a retrospective study from the European Group for 
Blood and Marrow Transplantation. Blood 2013;121:440–6.
[50] Kharfan-Dabaja MA, Al Malki MM, Deotare U, et al. Haematopoietic 
cell transplantation for blastic plasmacytoid dendritic cell neoplasm: 
a North American multicentre collaborative study. Br J Haematol 
2017;179:781–9.
[51] Aoki T, Suzuki R, Kuwatsuka Y, et al. Long-term survival following 
autologous and allogeneic stem cell transplantation for blastic 
plasmacytoid dendritic cell neoplasm. Blood 2015;125:3559–62.
[52] Reimer P, Rüdiger T, Kraemer D, et al. What is CD4+CD56+ malignancy 
and how should it be treated? Bone Marrow Transplant 2003;32:637–
46.
[53] Angelot-Delettre F, Roggy A, Frankel AE, et al. In vivo and in vitro 
sensitivity of blastic plasmacytoid dendritic cell neoplasm to sl-401, 
an interleukin-3 receptor targeted biologic agent. Haematologica 
2015;100:223–30.
[54] Sun W, Liu H, Kim Y, et al. First pediatric experience of SL-401, a CD123-
targeted therapy, in patients with blastic plasmacytoid dendritic cell 
neoplasm: report of three cases. J Hematol Oncol 2018;11:61.
A c t a  H a e m a t o l o g i c a  P o l o n i c a
244
[55] Sakashita K, Saito S, Yanagisawa R, et al. Usefulness of allogeneic 
hematopoietic stem cell transplantation in first complete remission 
for pediatric blastic plasmacytoid dendritic cell neoplasm with skin 
involvement: a case report and review of literature. Pediatr Blood 
Cancer 2013;60:E140–2.
[56] Grushchak S, Joy C, Gray A, et al. Novel treatment of blastic 
plasmacytoid dendritic cell neoplasm: a case report. Medicine 
(Baltimore) 2017;96:e9452.
[57] Marmouset V, Joris M, Merlusca L, et al. The lenalidomide/bortezomib/
dexamethasone regimen for the treatment of blastic plasmacytoid 
dendritic cell neoplasm. Hematol Oncol 2019;37:487–9.
[58] Montero J, Stephansky J, Cai T, et al. Blastic plasmacytoid dendritic 
cell neoplasm is dependent on BCL-2 and sensitive to venetoclax. 
Cancer Discov 2017;7:156–64.
[59] Emadali A, Hoghoughi N, Duley S, et al. Haploinsufficiency for 
NR3C1, the gene encoding the glucocorticoid receptor, in blastic 
plasmacytoid dendritic cell neoplasms. Blood 2016;127:3040–53.
[60] Ceroi A, Masson D, Roggy A, et al. LXR agonist treatment of blastic 
plasmacytoid dendritic cell neoplasm restores cholesterol efflux and 
triggers apoptosis. Blood 2016;128:2694–707.
[61] Kleppe M, Levine RL. An unexpected chink in the transcriptional armor 
of plasmacytoid dendritic neoplasms. Cancer Cell 2016;30:659–60.
[62] Ceribelli M, Hou ZE, Kelly PN, et al. A druggable TCF4- and BRD4-
dependent transcriptional network sustains malignancy in blastic 
plasmacytoid dendritic cell neoplasm. Cancer Cell 2016;30:764–78.
[63] Wiesner T, Obenauf AC, Cota C, Fried I, Speicher MR, Cerroni L. 
Alterations of the cell-cycle inhibitors p27 KIP1 and p16 INK4a are 
frequent in blastic plasmacytoid dendritic cell neoplasms. J Invest 
Dermatol 2010;130:1152–7.
[64] Sapienza MR, Abate F, Melle F, et al. Blastic plasmacytoid dendritic 
cell neoplasm: genomics mark epigenetic dysregulation as a primary 
therapeutic target. Haematologica 2019;104:729–37.
[65] Aung PP, Sukswai N, Nejati R, et al. PD1/PD-L1 expression in blastic 
plasmacytoid dendritic cell neoplasm. Cancers (Basel) 2019;11:695.
